Ac Immune Sa  (ACIU)
Other Ticker:  
Price: $2.3800 $-0.04 -1.653%
Day's High: $2.51 Week Perf: -1.65 %
Day's Low: $ 2.37 30 Day Perf: -26.88 %
Volume (M): 190 52 Wk High: $ 5.14
Volume (M$): $ 451 52 Wk Avg: $3.03
Open: $2.45 52 Wk Low: $1.78

 Market Capitalization (Millions $) 202
 Shares Outstanding (Millions) 85
 Employees 109
 Revenues (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -54
 Cash Flow (TTM) (Millions $) 32
 Capital Exp. (TTM) (Millions $) 1

Ac Immune Sa
AC Immune SA is a Swiss clinical-stage biopharmaceutical company specializing in the development of small molecule and biological therapeutics for neurodegenerative diseases. Founded in 2003, the company has become a leading player in the field of Alzheimer's disease and related disorders.

AC Immune's drug discovery platform is based on proprietary technology for identifying and developing small molecules and biological molecules that target misfolded proteins implicated in neurodegenerative diseases. The company has developed a suite of proprietary assays for identifying these molecules and has a deep understanding of the structural biology and pathology of these diseases.

AC Immune's lead drug candidate is crenezumab, a humanized monoclonal antibody that targets beta-amyloid, a protein that accumulates in the brains of Alzheimer's patients. The company is also developing tau-targeting antibodies, including semorinemab and ACI-3024, for the treatment of Alzheimer's and other tauopathies.

In addition to drug development, AC Immune has a strong pipeline of diagnostic products for the early detection and monitoring of neurodegenerative diseases. These include tests for beta-amyloid and tau biomarkers, as well as a blood test for Alzheimer's disease.

AC Immune has partnerships with several major pharmaceutical companies, including Genentech, Eli Lilly, and Janssen Pharmaceuticals. The company is headquartered in Lausanne, Switzerland, with additional offices in the United States and Canada.

Overall, AC Immune is a leading biopharmaceutical company in the field of neurodegenerative diseases, with a robust drug discovery platform and a strong focus on developing treatments for Alzheimer's disease and related disorders. The company's innovative approach to drug development and diagnostics offers hope for patients suffering from these devastating diseases.

   Company Address: EPFL INNOVATION PARK Lausanne 1015
   Company Phone Number: 21 345 91 21   Stock Exchange / Ticker: NASDAQ ACIU


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Ac Immune Sa

AC Immune SA Surges with $14.801 Million in Revenue, Stock Price Skyrockets by 42%

AC Immune SA, a major pharmaceutical preparations company, has seen a significant increase in its stock price over the past 30 days. The stock went up by 42.11%, bringing the share price to a 19.4% increase during the first quarter of 2024. Currently trading on the NASDAQ, the stock is 28.3% above its 52-week average.
In the fourth quarter of 2023 earnings season, AC Immune reported revenue of $14.801 million. This is a positive sign for the company, compared to a net deficit of $-70.753 million in the corresponding quarter of the previous year. Furthermore, AC Immune reported a net deficit of $-54.233 million for the fourth quarter of 2023, showing improvement.

Clinical Study

AC Immune Presents Promising Updates on Alzheimer's Disease Research at AD/PD 2024 Conference

Published Thu, Feb 22 2024 12:00 PM UTC

article for :AC Immune, a Swiss-based clinical-stage biopharmaceutical company focusing on precision medicine for neurodegenerative diseases, recently made significant announcements regarding its novel research findings in the fight against Alzheimer's disease (AD). The company presented these groundbreaking discoveries at the prestigious AD/PD 2024 Conference, shedding lig...

Licensing Agreement

AC Immune Takes Charge of Groundbreaking Alzheimer's Drug Candidates: Crenezumab and Semorinemab

Published Mon, Jan 22 2024 12:00 PM UTC

AC Immune, a Swiss-based biopharmaceutical company, has announced that it will regain the global rights to two of its key drug candidates, Crenezumab and Semorinemab. This decision comes as part of the company's strategy to strengthen and expand its portfolio in the field of neurodegenerative diseases, particularly Alzheimer's disease.Crenezumab is a monoclonal antibody that...

Management Changes

AC Immune Bolsters Leadership Team with New CSO and CFO Appointments

Published Fri, Dec 1 2023 12:00 PM UTC

In a strategic move to bolster its management team, AC Immune, a renowned Swiss-based biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, has appointed Madiha Derouazi as Chief Scientific Officer (CSO) and Christopher Roberts as Chief Financial Officer (CFO). These high-profile appointments reflect AC Immune's commitment to forging in...


Ac Immune Sa's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Ac Immune Sa does not provide revenue guidance.

Earnings Outlook
Ac Immune Sa does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com